PROCEPT BioRobotics is a surgical robotics company dedicated to advancing urology care. Co. develop, manufacture, and sell the AquaBeam Robotic System, an image-guided system for minimally invasive urologic surgery, primarily for treating benign prostatic hyperplasia (BPH). The AquaBeam system uses a single-use handpiece to deliver Aquablation therapy, which combines real-time imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation for precise prostate tissue removal. This therapy aims to provide effective, safe, and durable outcomes for men with lower urinary tract symptoms due to BPH, regardless of prostate size, shape, or surgeon experience. We show 16 historical shares outstanding datapoints in our coverage of PRCT's shares outstanding history.
Understanding the changing numbers of PRCT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRCT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRCT by allowing them to research PRCT shares outstanding history
as well as any other stock in our coverage universe. |
Free PRCT Email Alerts:
Video: Shares Outstanding Importance
